Target Information

Target General Infomation
Target ID
T83797
Former ID
TTDC00194
Target Name
Hepatocyte growth factor
Gene Name
HGF
Synonyms
Hepatopoeitin A; SF; Scatter factor; HGF
Target Type
Clinical Trial
Disease Angina pectoris; Peripheral arterial disease [ICD9:413, 443; ICD10: I20, I73]
Advanced malignancies [ICD9: 140-229; ICD10: C00-C96]
Grade IV malignant glioma; Glioblastoma multiforme [ICD9: 191; ICD10: C71]
Function
Hgf is a potent mitogenfor mature parenchymal hepatocyte cells, seems to be an hepatotrophic factor, and acts as growth factor for a broad spectrum of tissues and cell types. It has no detectable protease activity.
BioChemical Class
Peptidase
Target Validation
T83797
UniProt ID
P14210
Sequence
MWVTKLLPALLLQHVLLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTLIKIDPALKIK
TKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDLYE
NKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCRNP
RGEEGGPWCFTSNPEVRYEVCDIPQCSEVECMTCNGESYRGLMDHTESGKICQRWDHQTP
HRHKFLPERYPDKGFDDNYCRNPDGQPRPWCYTLDPHTRWEYCAIKTCADNTMNDTDVPL
ETTECIQGQGEGYRGTVNTIWNGIPCQRWDSQYPHEHDMTPENFKCKDLRENYCRNPDGS
ESPWCFTTDPNIRVGYCSQIPNCDMSHGQDCYRGNGKNYMGNLSQTRSGLTCSMWDKNME
DLHRHIFWEPDASKLNENYCRNPDDDAHGPWCYTGNPLIPWDYCPISRCEGDTTPTIVNL
DHPVISCAKTKQLRVVNGIPTRTNIGWMVSLRYRNKHICGGSLIKESWVLTARQCFPSRD
LKDYEAWLGIHDVHGRGDEKCKQVLNVSQLVYGPEGSDLVLMKLARPAVLDDFVSTIDLP
NYGCTIPEKTSCSVYGWGYTGLINYDGLLRVAHLYIMGNEKCSQHHRGKVTLNESEICAG
AEKIGSGPCEGDYGGPLVCEQHKMRMVLGVIVPGRGCAIPNRPGIFVRVAYYAKWIHKII
LTYKVPQS
Drugs and Mode of Action
Drug(s) VM-202 Drug Info Phase 3 Angina pectoris; Peripheral arterial disease [525174]
TAK-701 Drug Info Phase 1 Advanced malignancies [522563]
Rilotumumab Drug Info Discontinued in Phase 2 Grade IV malignant glioma; Glioblastoma multiforme [542900], [547311]
Inhibitor N,O6-Disulfo-Glucosamine Drug Info [551393]
O2-Sulfo-Glucuronic Acid Drug Info [551393]
Modulator TAK-701 Drug Info
VM-202 Drug Info [529590]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
PI3K-Akt signaling pathway
Focal adhesion
Malaria
Pathways in cancer
Proteoglycans in cancer
Renal cell carcinoma
Melanoma
NetPath Pathway EGFR1 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
TNFalpha Signaling Pathway
Pathway Interaction Database Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
Arf6 signaling events
Signaling events mediated by TCPTP
Direct p53 effectors
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
Syndecan-1-mediated signaling events
Stabilization and expansion of the E-cadherin adherens junction
FGF signaling pathway
Reactome Platelet degranulation
Interleukin-7 signaling
WikiPathways Signaling of Hepatocyte Growth Factor Receptor
Focal Adhesion
NRF2 pathway
Nuclear Receptors Meta-Pathway
Extracellular vesicle-mediated signaling in recipient cells
Differentiation Pathway
Interleukin-7 signaling
Prostate Cancer
References
Ref 522563ClinicalTrials.gov (NCT00831896) Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies. U.S. National Institutes of Health.
Ref 525174ClinicalTrials.gov (NCT02427464) Phase 3 Gene Therapy for Painful Diabetic Neuropathy. U.S. National Institutes of Health.
Ref 542900(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7986).
Ref 547311Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015060)
Ref 529590Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model. Eur J Cardiothorac Surg. 2008 Oct;34(4):857-63.
Ref 536533AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6735-42.
Ref 550250Clinical pipeline report, company report or official report of Amgen (2009).
Ref 551393How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.